[go: up one dir, main page]

NO20091064L - Antistoffer mot IL-17A - Google Patents

Antistoffer mot IL-17A

Info

Publication number
NO20091064L
NO20091064L NO20091064A NO20091064A NO20091064L NO 20091064 L NO20091064 L NO 20091064L NO 20091064 A NO20091064 A NO 20091064A NO 20091064 A NO20091064 A NO 20091064A NO 20091064 L NO20091064 L NO 20091064L
Authority
NO
Norway
Prior art keywords
antibodies
human
modified antibodies
summary modified
modified
Prior art date
Application number
NO20091064A
Other languages
English (en)
Inventor
Leonard G Presta
Edward P Bowman
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20091064L publication Critical patent/NO20091064L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Sammendrag Modifiserte antistoffer mot humant IL- I 7A samt anvendelser derav tilveiebringes.
NO20091064A 2006-08-11 2009-03-10 Antistoffer mot IL-17A NO20091064L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83719706P 2006-08-11 2006-08-11
PCT/US2007/017679 WO2008021156A2 (en) 2006-08-11 2007-08-09 Antibodies to il-17a

Publications (1)

Publication Number Publication Date
NO20091064L true NO20091064L (no) 2009-05-07

Family

ID=38926184

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091064A NO20091064L (no) 2006-08-11 2009-03-10 Antistoffer mot IL-17A

Country Status (18)

Country Link
US (3) US7846443B2 (no)
EP (1) EP2046835B1 (no)
JP (2) JP5118699B2 (no)
KR (1) KR101218484B1 (no)
CN (1) CN101646690B (no)
AR (1) AR063683A1 (no)
AT (1) ATE530578T1 (no)
AU (1) AU2007284782B2 (no)
BR (1) BRPI0715917A2 (no)
CA (1) CA2660463C (no)
ES (1) ES2373069T3 (no)
IL (1) IL196968A (no)
MX (1) MX2009001620A (no)
NO (1) NO20091064L (no)
NZ (1) NZ574804A (no)
PE (1) PE20080739A1 (no)
WO (1) WO2008021156A2 (no)
ZA (1) ZA200901402B (no)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790163B2 (en) 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
EP1996622A2 (en) 2006-03-10 2008-12-03 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
AU2007284782B2 (en) * 2006-08-11 2012-11-15 Merck Sharp & Dohme Corp. Antibodies to IL-17A
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
TWI426918B (zh) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
AU2008219681A1 (en) 2007-02-28 2008-09-04 Merck Sharp & Dohme Corp. Combination therapy for treatment of immune disorders
US20100239590A1 (en) * 2007-06-20 2010-09-23 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
WO2009015063A2 (en) * 2007-07-23 2009-01-29 Centocor Methods and compositions for treating fibrosis related disorders using il-17 antagonists
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
EP2337799A2 (en) * 2008-08-28 2011-06-29 Wyeth LLC Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
RU2539029C2 (ru) * 2008-09-29 2015-01-10 Роше Гликарт Аг Антитела против интерлейкина 17 (ил-17) человека и их применение
RU2015132478A (ru) 2009-03-05 2015-12-10 Эббви Инк. Связывающие il-17 белки
MY159837A (en) 2009-08-29 2017-02-15 Abbvie Inc Therapeutic dll4 binding proteins
US8911722B2 (en) * 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
AU2010303166A1 (en) * 2009-10-10 2012-05-24 Eleven Biotherapeutics, Inc. IL-17 family cytokine compositions and uses
US8519107B2 (en) * 2009-10-30 2013-08-27 Janssen Biotech, Inc. IL-17A antibodies
SG183872A1 (en) * 2010-03-02 2012-11-29 Abbvie Inc Therapeutic dll4 binding proteins
US20110293629A1 (en) 2010-05-14 2011-12-01 Bastid Jeremy Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
US9328166B2 (en) * 2010-08-05 2016-05-03 Anaptysbio, Inc. Antibodies directed against IL-17
CN103328505B (zh) * 2010-10-29 2015-12-02 伊缪诺金公司 非拮抗性egfr结合分子及其免疫偶联物
WO2012058588A2 (en) 2010-10-29 2012-05-03 Immunogen, Inc. Novel egfr-binding molecules and immunoconjugates thereof
RS56298B1 (sr) 2011-01-14 2017-12-29 Ucb Biopharma Sprl Antitelo koje vezuje il-17a i il-17f
WO2013078271A1 (en) 2011-11-21 2013-05-30 Immunogen, Inc. Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
ES2711554T3 (es) 2012-05-22 2019-05-06 Bristol Myers Squibb Co Anticuerpos biespecíficos contra IL-17A/F IL-23 y sus usos
BR112015012458A2 (pt) 2012-11-29 2018-02-06 Bayer Healthcare Llc anticorpos monoclonais humanizados contra a proteína c ativada e usos destes
EP2953969B1 (en) 2013-02-08 2019-08-28 Novartis AG Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
EP3072905B1 (en) 2013-11-18 2020-08-19 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-17a binding agent and uses thereof
US20160340422A1 (en) * 2014-01-28 2016-11-24 Beijing Hanmi Pharmaceutical Co., Ltd. Bifunctional fusion protein, preparation method therefor, and use thereof
US9476066B2 (en) 2014-03-06 2016-10-25 Iogen Corporation Production of products with favourable GHG emission reductions from cellulosic feedstocks
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
US9982061B2 (en) 2014-10-01 2018-05-29 Medimmune Limited Antibodies to ticagrelor and methods of use
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
GB201500463D0 (en) 2015-01-12 2015-02-25 Cresendo Biolog Ltd Therapeutic molecules
CN108251431B (zh) 2015-03-05 2020-12-08 北京百特美博生物科技有限公司 双载体系统及其用途
AU2016229060A1 (en) * 2015-03-09 2017-09-28 The Regents Of The Universtiy Of Michigan Materials and methods for eliciting targeted antibody responses in vivo
IL257324B (en) 2015-08-03 2022-08-01 Carsgen Therapeutics Ltd Antibody against glypican-3 and its use
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
EP3220145A1 (en) * 2016-03-17 2017-09-20 Universiteit Antwerpen Identification of subjects at risk of developing ventilator-associated pneumonia
CN109715660A (zh) 2016-09-14 2019-05-03 北京韩美药品有限公司 一种能够特异性地结合il-17a的抗体及其功能片段
CN109206515B (zh) * 2017-07-06 2021-10-12 北京伟峰益民科技有限公司 一种全人源抗人白介素17a抗体及其应用
CN107522783B (zh) * 2017-09-30 2020-07-07 华博生物医药技术（上海）有限公司 一种抗白介素17a的抗体、其制备方法和应用
EP3773717A4 (en) * 2018-03-29 2022-05-11 REMD Biotherapeutics, Inc. TREATMENT OF AUTOIMMUNE AND INFLAMMATION DISEASES WITH ANTIBODIES THAT BIND INTERLEUKIN-17A (IL-17A).
CN113302203A (zh) 2018-10-30 2021-08-24 美真达治疗公司 抗cd45抗体及其缀合物
TWI825214B (zh) 2018-11-05 2023-12-11 中國大陸商北京韓美藥品有限公司 抗TNFα/抗IL-17A天然抗體結構樣異源二聚體形式雙特異抗體及其製備
CN111303283A (zh) 2018-12-12 2020-06-19 上海君实生物医药科技股份有限公司 抗il-17a抗体及其应用
MA54857A (fr) 2019-01-31 2021-12-08 Numab Therapeutics AG Anticorps multispécifiques ayant une spécificité pour tnfa et il-17a, anticorps ciblant il-17a, et leurs procédés d'utilisation
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
EP4006053A4 (en) * 2019-07-30 2022-10-26 Jiangsu Hengrui Medicine Co., Ltd. METHOD OF TREATMENT OF AN AUTOIMMUNE DISEASE WITH AN IL-17 ANTAGONIST
CN115746132B (zh) * 2021-09-03 2023-09-08 三优生物医药(上海)有限公司 抗il-17a抗体及其用途
CN114380906B (zh) * 2022-03-25 2022-06-14 南京融捷康生物科技有限公司 一种抗il-17a的单域抗体及其用途
CN116751277A (zh) * 2023-01-10 2023-09-15 武汉爱博泰克生物科技有限公司 利用毕赤酵母表达活性重组人il-17a蛋白的方法
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274711B1 (en) 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
WO2004071517A2 (en) 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
GB0312481D0 (en) * 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
ATE395083T1 (de) 2003-11-21 2008-05-15 Ucb Pharma Sa Verfahren zur behandlung von multipler sklerose durch hemmung der il-17-aktivität
JP2007535930A (ja) 2004-05-03 2007-12-13 シェーリング　コーポレイション 皮膚の炎症を予測するためのｉｌ−１７発現の使用；処置方法
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
LT2481753T (lt) * 2005-12-13 2018-05-25 Eli Lilly And Company Anti-il-17 antikūnai
EP1996622A2 (en) 2006-03-10 2008-12-03 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
CA2655372A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
AU2007284782B2 (en) * 2006-08-11 2012-11-15 Merck Sharp & Dohme Corp. Antibodies to IL-17A

Also Published As

Publication number Publication date
EP2046835A2 (en) 2009-04-15
AU2007284782A1 (en) 2008-02-21
US20110038878A1 (en) 2011-02-17
US7846443B2 (en) 2010-12-07
JP2013009680A (ja) 2013-01-17
JP5118699B2 (ja) 2013-01-16
US8193319B2 (en) 2012-06-05
CN101646690B (zh) 2013-10-23
JP2010500028A (ja) 2010-01-07
BRPI0715917A2 (pt) 2014-11-25
CA2660463C (en) 2013-07-16
WO2008021156A3 (en) 2008-07-03
MX2009001620A (es) 2009-02-23
CN101646690A (zh) 2010-02-10
ATE530578T1 (de) 2011-11-15
AU2007284782B2 (en) 2012-11-15
EP2046835B1 (en) 2011-10-26
ZA200901402B (en) 2010-02-24
US20110052596A1 (en) 2011-03-03
PE20080739A1 (es) 2008-06-14
IL196968A (en) 2013-08-29
US8753843B2 (en) 2014-06-17
AR063683A1 (es) 2009-02-11
NZ574804A (en) 2012-02-24
IL196968A0 (en) 2011-08-01
CA2660463A1 (en) 2008-02-21
ES2373069T3 (es) 2012-01-31
KR20090052347A (ko) 2009-05-25
US20090175881A1 (en) 2009-07-09
KR101218484B1 (ko) 2013-01-04
WO2008021156A2 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
NO20091064L (no) Antistoffer mot IL-17A
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
HUS2100053I1 (hu) Interleukin-13-antitest-készítmény
CY2018013I2 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1116261T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
PT1920065T (pt) Anticorpos anti-alfavbeta6 e suas utilizações
CY2017039I2 (el) Αντισωματα υψηλης συγγενειας στον υποδοχεα της ανθρωπινης ιl-6
DK2222706T3 (da) Antibodies against human nkg2d and uses thereof
CY1118343T1 (el) Αντισωματα συνδεσης twεακ
DK1991584T3 (da) Antistoffer mod human IL-22 og anvendelser deraf
EP1964852A4 (en) ANTI-ILT7 ANTIBODY
CR20120210A (es) Proteínas de enlace al antigeno il-23 humanas
RU2426741C3 (ru) Антагонистические антитела к il-17
DK2032606T3 (da) Antistoffer og immunkonjugater og anvendelser deraf
DK2327423T3 (da) Humane antistoffer mod humant interleukin-22 (IL-22)
IL225372A0 (en) Antibodies directed to her-3 and uses thereof
DK1951273T3 (da) Anvendelse af lactobacillus til behandling af autoimmune sygdomme
EP2142214A4 (en) ANTI-IGE ANTIBODY
EP1912533A4 (en) IMPROVED FOOT STARTER
EP1765396A4 (en) ANTIBODY
DE502005002101D1 (de) Komposit-membran
EP2274332A4 (en) ANTI-TNF ANTIBODY
DE602006014044D1 (de) Pedalsystem
EA201070637A1 (ru) Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н
FI20061034L (fi) Kaksiportainen ahtopuristusjärjestelmä

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP, US

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY

FC2A Withdrawal, rejection or dismissal of laid open patent application